FDA seeks data for Sentinel Initiative
The FDA plans to begin collecting information for its Sentinel Initiative, according to Federal Register announcement.
The FDA plans to begin collecting information for its Sentinel Initiative, according to Federal Register announcement. The initiative, established in May 2008, focuses on enabling the agency to improve the monitoring of drug performance after marketing approval by working with multiple healthcare data systems. The 2007 FDA Amendments Act calls for the agency to access data from 25 million patients by July 2010 and from 100 million patients by July 2012, according to the announcement.
"The proposed system will enable queries of distributed data sources quickly and securely for relevant product safety information," says the announcement. "Data will continue to be managed by its owners and only data of organizations who agree to participate in this system will be included."
The call for data, which will help the FDA plan for this proposed system and for future work related to the Sentinel Initiative, has been submitted for approval to the Office for Management and Budget. The data sought includes the scope, content, structure, quality, and timeliness of data; patient population(s), duration of followup, and capture of care across all settings; availability, experience and interest of investigators with knowledge of the data in using it for postmarket product safety surveillance as well as plans for further data source enhancements; availability, experience, and interest of investigators with knowledge of the data in participating in a distributed data system; and barriers that exist to including each data source in the Sentinel Initiative.
The agency estimates that each respondent submitting the above information will spend approximately 24.5 hours doing so. The FDA expects 250 respondents to participate in the survey.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.
